Clinical Trials on CCND1 Protein Overexpression in Brazil

Total 123 results

Silvia Leite Faria
University of Brasilia

Completed

Diet-induced Thermogenesis in Patients With Postoperative Roux-in-Y Gastric Bypass (RYGBP) Weight Regain (RYGBP)

Obesity | Bariatric Surgery Candidate | Protein-energy; Imbalance

Brazil
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento... and other collaborators

Completed

Acute Whey Protein And Casein Supplementation: Effect On Protein Metabolism After Resistance Exercise

Protein Supplementation | Sports Nutrition

Brazil
University of Nove de Julho

Unknown

Use of Low-level Laser Therapy on Children Aged One to Five Years With Energy-protein Malnutrition

Malnutrition, Child

Brazil
University of Sao Paulo General Hospital

Unknown

Protein Supplementation: Body Composition, Muscle Strength and Postural Balance

Diabetes Mellitus, Type 2 | Body Composition | Resistance Training | Protein Supplementation | Inflammation Biomarkers

Brazil
Hospital de Clinicas de Porto Alegre

Completed

Comparison of the Increment of Neuromuscular Parameters in Vegetarians and Non-vegetarians

Hypertrophy | Muscle Strength | Dietary Proteins | Strength Training

Brazil
Grupo de Estudos Multicentricos em Onco-Hematologia

Unknown

Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation (MAXDARA)

Multiple Myeloma Stage I

Brazil
Hospital Israelita Albert Einstein

Completed

The Nutritionist's Educational Intervention on the Protein Intake in Hospitalized Elderly People

Sarcopenia | Dietary Habits | Patient Participation | Protein Malnutrition | Old Age; Cachexia

Brazil
University of Campinas, Brazil

Unknown

Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma (METDEXA-MM)

Multiple Myeloma

Brazil
Instituto do Cancer do Estado de São Paulo

Recruiting

Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma

Multiple Myeloma

Brazil
Federal University of Health Science of Porto Alegre

Unknown

Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation

Lymphoma | Leukemia | Fatigue | Multiple Myeloma | Hematopoietic Stem Cell Transplantation

Brazil
Federal University of São Paulo
CSL Behring

Completed

Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin

Common Variable Immunodeficiency | Agammaglobulinemia

Brazil
The Hospital for Sick Children
Baxter Healthcare Corporation; University of Sao Paulo; University of Campinas... and other collaborators

Completed

Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles

Hemophilia | Hemophilic Arthropathy

Canada, Brazil
The Hospital for Sick Children

Completed

Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World

Hemophilia A | Hemophilia B

Canada, Brazil
Novo Nordisk A/S

Completed

To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives (HERO)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B | Relatives to/Carers of Patients

Brazil
Grupo de Estudos Multicentricos em Onco-Hematologia

Completed

Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma

Multiple Myeloma

Brazil
University of Sao Paulo General Hospital

Completed

Viscosupplementation in Patients With Hemophilic Arthropathy

Hemophilia A | Hemophilia B | Osteoarthritis | Hemarthrosis

Brazil
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Brazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
Grupo de Estudos Multicentricos em Onco-Hematologia

Unknown

Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years

Multiple Myeloma

Brazil
Takeda

Withdrawn

A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation (IDEALL)

Multiple Myeloma

Brazil
BioMarin Pharmaceutical

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3)

Hemophilia A

United States, Australia, Taiwan, Brazil
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

United States, Australia, Brazil, Italy, United Kingdom
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Takeda

Completed

Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis (MMyBRave)

Multiple Myeloma

Brazil
Janssen-Cilag Ltd.

Completed

A Registry Study of Participants With Multiple Myeloma in Latin America (MYLACRE)

Multiple Myeloma

Brazil, Argentina, Mexico, Colombia, Panama
Christian Medical College, Vellore, India

Unknown

Musculoskeletal Function in Hemophilia

Hemophilia

India, Argentina, Brazil, Egypt, Iran, Islamic Republic of, Singapore, South Africa, Thailand, Venezuela
Baxalta now part of Shire

Completed

IMMUNINE Pre-Treatment Study

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Brazil, Czechia, Russian Federation, Ukraine
BioMarin Pharmaceutical

Recruiting

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors (GENEr8-INH)

Hemophilia A With Inhibitor | Hemophilia A With Anti Factor VIII

United States, United Kingdom, Taiwan, Israel, Korea, Republic of, South Africa, Brazil, Italy, Germany
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)

Multiple Myeloma

Australia, Poland, Taiwan, Korea, Republic of, Japan, United Kingdom, Brazil, Mexico, Turkey, Argentina
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
AstraZeneca

Terminated

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Elevated High-sensitivity C-Reactive Protein (hsCRP)

United States, Brazil, Bulgaria, Poland, Russian Federation, South Africa, United Kingdom, Germany, Estonia, Romania, Denmark, Netherlands, Norway, Canada, Mexico, Belgium, Israel, Puerto Rico, Colombia, Argentina, Venezuela, Panama, Urugu... and more
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
Sanofi

Active, not recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia, Czechia, Brazil, Japan, Greece, Portugal
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood (Alfa-PROTECT)

Hemophilia A | Children | Prophylaxis of Bleeding | Treatment of Bleeding

Canada, United States, Brazil, Italy, Turkey, Argentina, Norway
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)

Severe Hemophilia A | Moderate Hemophilia A

Brazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
Pfizer

Active, not recruiting

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (AFFINE)

Hemophilia A

Spain, Taiwan, Australia, United States, Japan, France, Turkey, Germany, Korea, Republic of, United Kingdom, Saudi Arabia, Canada, Greece, Sweden, Brazil, Italy
Baxalta now part of Shire

Completed

BAX 326 (rFIX) Continuation Study

Hemophilia B

Taiwan, Colombia, Argentina, Brazil, Bulgaria, Chile, Czechia, India, Ireland, Italy, Japan, Poland, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Completed

Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET)

Hemophilia A

United States, India, Spain, Argentina, Austria, Brazil, Chile, Egypt, Iran, Islamic Republic of, Italy, Mexico, Saudi Arabia, South Africa, Turkey
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7)

Severe Hemophilia A

Canada, United States, United Kingdom, Belgium, Australia, Austria, Brazil, France, Germany, Israel, Italy, South Africa, Spain, Turkey
BioMarin Pharmaceutical

Active, not recruiting

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) (BMN 270-301)

Hemophilia A

United States, Taiwan, United Kingdom, Australia, Israel, Belgium, Brazil, France, Germany, Italy, Korea, Republic of, South Africa, Spain
Sanofi

Completed

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Plasma Cell Myeloma

France, Italy, Czechia, Greece, Spain, Canada, Australia, United States, Brazil, Hungary
Bioverativ, a Sanofi company

Completed

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A (XTEND-1)

Factor VIII Deficiency

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Spain, Taiwan, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Saudi Arabia, Germany, Singapore, Italy, France, Israel, United Kingdom, Japan, Australia, Spain, Brazil, United States, Greece, Canada
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Belgium, Korea, Republic of, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Czechia, Brazil, Netherlands, Poland, Switzerland, Norway, Germany
Janssen-Cilag Ltd.

Completed

Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America (HOLA)

Lymphoma | Leukemia | Multiple Myeloma | Non-Hodgkin | Lymphoid

Argentina, Colombia, Mexico, Panama, Brazil, Chile, Guatemala
Eli Lilly and Company

Completed

A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

Multiple Myeloma

Mexico, United States, Germany, Italy, France, Poland, Taiwan, Spain, Turkey, United Kingdom, Korea, Republic of, Greece, Canada, Brazil, Netherlands
ApcinteX Ltd
Centessa Pharmaceuticals plc

Recruiting

Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

Hemophilia A | Hemophilia B

Spain, Taiwan, United Kingdom, Italy, Germany, United States, South Africa, Australia, Poland, Armenia, France, India, Canada, Brazil, Turkey, Egypt

Clinical Trials on CCND1 Protein Overexpression in Brazil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations